CN101175532B - 包含一种抗寄生虫药物和一种选自香芹醇、麝香草酚、丁香酚、樟醇、香芹酚、α-紫罗兰酮或β-紫罗兰酮的活性成分的药物组合物 - Google Patents

包含一种抗寄生虫药物和一种选自香芹醇、麝香草酚、丁香酚、樟醇、香芹酚、α-紫罗兰酮或β-紫罗兰酮的活性成分的药物组合物 Download PDF

Info

Publication number
CN101175532B
CN101175532B CN2006800161609A CN200680016160A CN101175532B CN 101175532 B CN101175532 B CN 101175532B CN 2006800161609 A CN2006800161609 A CN 2006800161609A CN 200680016160 A CN200680016160 A CN 200680016160A CN 101175532 B CN101175532 B CN 101175532B
Authority
CN
China
Prior art keywords
active substance
carvacrol
eugenol
group
therapeutically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800161609A
Other languages
English (en)
Chinese (zh)
Other versions
CN101175532A (zh
Inventor
阿德南·雷梅尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ADVENCED SCIENT DEVELOPEMENTS
Original Assignee
ADVENCED SCIENT DEVELOPEMENTS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ADVENCED SCIENT DEVELOPEMENTS filed Critical ADVENCED SCIENT DEVELOPEMENTS
Publication of CN101175532A publication Critical patent/CN101175532A/zh
Application granted granted Critical
Publication of CN101175532B publication Critical patent/CN101175532B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2006800161609A 2005-05-13 2006-05-15 包含一种抗寄生虫药物和一种选自香芹醇、麝香草酚、丁香酚、樟醇、香芹酚、α-紫罗兰酮或β-紫罗兰酮的活性成分的药物组合物 Expired - Fee Related CN101175532B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
WOPCT/IB2005/001314 2005-05-13
PCT/IB2005/001314 WO2006120495A1 (fr) 2005-05-13 2005-05-13 Composition pharmaceutique comprenant un antiviral, an antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol, le thymol, l’eugenol, le borneol et le carvacrol
IBPCT/IB2005/001314 2005-05-13
PCT/IB2006/001441 WO2006120568A2 (fr) 2005-05-13 2006-05-15 Composition pharmaceutique comprenant un agent antiparasitaire , et un actif choisi parmi le carveol , le thymol , l ugenol , le borneol , le carvacrol , l lpha- ionone ou le beta-ionone

Publications (2)

Publication Number Publication Date
CN101175532A CN101175532A (zh) 2008-05-07
CN101175532B true CN101175532B (zh) 2011-12-28

Family

ID=35427309

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2006800161609A Expired - Fee Related CN101175532B (zh) 2005-05-13 2006-05-15 包含一种抗寄生虫药物和一种选自香芹醇、麝香草酚、丁香酚、樟醇、香芹酚、α-紫罗兰酮或β-紫罗兰酮的活性成分的药物组合物
CN2006800203654A Expired - Fee Related CN101193682B (zh) 2005-05-13 2006-05-15 包含一种抗病毒、一种抗肿瘤或一种抗寄生虫药以及一种选自香芹醇、麝香草酚、丁香酚、樟醇和香芹酚的活性物质的药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2006800203654A Expired - Fee Related CN101193682B (zh) 2005-05-13 2006-05-15 包含一种抗病毒、一种抗肿瘤或一种抗寄生虫药以及一种选自香芹醇、麝香草酚、丁香酚、樟醇和香芹酚的活性物质的药物组合物

Country Status (16)

Country Link
US (2) US20080171768A1 (https=)
EP (2) EP1879656B1 (https=)
JP (1) JP5073651B2 (https=)
CN (2) CN101175532B (https=)
AP (1) AP2437A (https=)
AT (1) ATE554827T1 (https=)
BR (2) BRPI0610123A2 (https=)
CA (2) CA2608061C (https=)
DK (2) DK1883452T3 (https=)
EA (1) EA015168B1 (https=)
ES (2) ES2386292T3 (https=)
MA (2) MA29573B1 (https=)
PT (2) PT1883452E (https=)
TN (2) TNSN07423A1 (https=)
WO (3) WO2006120495A1 (https=)
ZA (1) ZA200710785B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113042A1 (en) * 2006-09-05 2008-05-15 Chu Kee Hung Pharmaceutical composition and method for cancer treatment based on combinational use of conventional anticancer agents and geranium oil or compounds thereof
US20080293648A1 (en) * 2007-01-05 2008-11-27 Saha Pharmaceuticals, Inc. Compositions and Methods for Cancer Treatment
BRPI1009199A2 (pt) 2009-03-17 2016-03-08 Concert Pharmaceuticals Inc compostos de pirazinoisoquinolina
AU2010297406B2 (en) 2009-09-24 2013-10-17 Unilever Plc Disinfecting agent comprising eugenol, terpineol and thymol
WO2012076310A1 (en) 2010-12-07 2012-06-14 Unilever Nv An oral care composition
MX2014005405A (es) 2011-11-03 2014-06-23 Unilever Nv Una composicion de limpieza personal.
CN102579449B (zh) * 2012-03-30 2013-08-07 厦门大学 一种可提高肿瘤对紫杉醇敏感性的联合用药
GB201404505D0 (en) * 2013-09-06 2014-04-30 Mars Inc Oral anti-parasitic composition
KR20170052626A (ko) 2014-09-05 2017-05-12 심바이오믹스 세러퓨틱스 엘엘씨 세균질증 치료에 사용하기 위한 세크니다졸
CN107405404A (zh) * 2015-03-20 2017-11-28 塞米·欧尤·奥皮约 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途
US11253501B2 (en) 2015-06-01 2022-02-22 Lupin Inc. Secnidazole formulations and use in treating bacterial vaginosis
CN105147647A (zh) * 2015-08-19 2015-12-16 华南理工大学 右旋龙脑作为抗肿瘤药物增敏剂的应用
WO2017209588A2 (fr) 2016-06-02 2017-12-07 Advanced Scientific Developements Formulation pharmaceutique de cinéol et d'amoxicilline
CA3057858A1 (en) * 2017-03-28 2018-10-04 IRP Health Pty Ltd Berberine alkaloids in the prevention and/or treatment of intestinal disease
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations
US12280037B2 (en) 2020-09-22 2025-04-22 Evofem Biosciences, Inc. Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof
CN112972437B (zh) * 2021-02-19 2022-03-25 沈阳伟嘉生物技术有限公司 一种包含碘硝酚的长效外用制剂及其制备方法和用途
CN121550195A (zh) * 2026-01-21 2026-02-24 哈尔滨医科大学 β-紫罗兰酮在制备肿瘤免疫调节剂中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1683317A (zh) * 2005-03-07 2005-10-19 常州市智能动物药业有限公司 百里酚和/或香芹酚的酯类化合物、制备方法及其药物活性组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3634697A1 (de) * 1986-10-11 1988-04-21 Dentaire Ivoclar Ets Dentalwerkstoff zur bekaempfung von karies und parodontose
DE19509697A1 (de) * 1995-03-08 1996-09-12 Schering Ag Neue Borneole, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US20020182268A1 (en) * 1998-12-07 2002-12-05 Bessette Steven M. Cancer treatment compositions and method using natural plant essential oils
US6536268B1 (en) * 1999-11-01 2003-03-25 Siemens Vdo Automotive Corporation Utilizing increasing width for identification voltages
DE10007771A1 (de) * 2000-02-14 2001-08-23 Kleine & Steube Entoxin Gmbh Immunmodulatorisch wirksame Zusammensetzungen, Verfahren zu ihrer Herstellung und ihre Verwendung
US20050014827A1 (en) * 2000-11-09 2005-01-20 Schur Jorg P. Synergistic medicament containing flavoring agents and having an antagonistic regenerative and/or protagonist decontamination effect
WO2002053138A2 (en) * 2001-01-02 2002-07-11 Elisabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US20030064948A1 (en) * 2001-02-08 2003-04-03 Alfred Fahr Invasomes for therapy of disorders, their preparation and use
ATE478684T1 (de) * 2002-02-20 2010-09-15 Ninkov Dusan Dr Antimikrobielle therapeutische zusammensetzungen und ihre verwendung
US20030225003A1 (en) * 2002-04-18 2003-12-04 Dusan Ninkov Antimicrobial therapeutic compositions for oral and topical use
EA200500804A1 (ru) * 2002-12-10 2005-12-29 Биосинексус Инкорпорейтед Топические противоинфекционные композиции
US20040151771A1 (en) * 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1683317A (zh) * 2005-03-07 2005-10-19 常州市智能动物药业有限公司 百里酚和/或香芹酚的酯类化合物、制备方法及其药物活性组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BAILENGER，J.ET AL.A new anthelmintic:piperazine thymolsulfonate.I.Experimental study.《BULLETIN DES TRAVAUX DE LA SOCIETE DE PHARMACIE DE BORDEAUX》.1955,(第93期),第162-166页. *

Also Published As

Publication number Publication date
EA200702486A1 (ru) 2008-06-30
TNSN07426A1 (fr) 2009-03-17
PT1883452E (pt) 2013-02-18
TNSN07423A1 (fr) 2009-03-17
DK1883452T3 (da) 2013-02-25
BRPI0610123A2 (pt) 2012-09-25
MA29573B1 (fr) 2008-06-02
US20080171709A1 (en) 2008-07-17
ES2399348T3 (es) 2013-03-27
WO2006120564A1 (fr) 2006-11-16
CN101193682A (zh) 2008-06-04
CN101193682B (zh) 2012-06-13
ES2386292T3 (es) 2012-08-16
CA2606887C (fr) 2014-07-15
EA015168B1 (ru) 2011-06-30
CN101175532A (zh) 2008-05-07
EP1879656B1 (fr) 2012-04-25
DK1879656T3 (da) 2012-07-23
CA2608061A1 (fr) 2006-11-16
JP5073651B2 (ja) 2012-11-14
WO2006120495A1 (fr) 2006-11-16
CA2606887A1 (fr) 2006-11-16
AP2437A (en) 2012-08-31
AP2007004228A0 (en) 2007-12-31
US20080171768A1 (en) 2008-07-17
EP1883452A2 (fr) 2008-02-06
JP2008540505A (ja) 2008-11-20
PT1879656E (pt) 2012-07-25
ATE554827T1 (de) 2012-05-15
EP1879656A1 (fr) 2008-01-23
EP1883452B1 (fr) 2012-12-19
CA2608061C (fr) 2014-07-15
WO2006120568A2 (fr) 2006-11-16
WO2006120568A3 (fr) 2007-08-23
MA29908B1 (fr) 2008-11-03
ZA200710785B (en) 2009-06-24
BRPI0610130A2 (pt) 2012-09-25

Similar Documents

Publication Publication Date Title
CN101175532B (zh) 包含一种抗寄生虫药物和一种选自香芹醇、麝香草酚、丁香酚、樟醇、香芹酚、α-紫罗兰酮或β-紫罗兰酮的活性成分的药物组合物
DE60117615T2 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
Jay et al. Pharmacokinetics, bioavailability, and hemodynamic effects of trazodone after intravenous and oral administration of a single dose to dogs
US6693125B2 (en) Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
CN101357146A (zh) 山蜡梅有效部位群的制备方法及其制剂的制法与用途
CN101926813A (zh) 兽用复方抗寄生虫注射液及其制备方法
CN101780082A (zh) 双苄基异喹啉类生物碱作为抗感染药物增效剂的用途及其药物组合物
Horiuchi et al. The effect of free and polyethylene glycol–liposome-entrapped albendazole on larval mobility and number in Toxocara canis infected mice
Sordet et al. Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis
Page et al. Comparative pharmacokinetics of trimethoprim-sulfamethoxazole administered intravenously and orally to captive elephants
US20160339057A1 (en) Novel composition method of using the same for the treatment of lyme disease
Bo et al. Evaluation of optimum conditions for decoquinate nanoliposomes and their anticoccidial efficacy against diclazuril-resistant Eimeria tenella infections in broilers
Elfawal et al. Artemisia annua and artemisinins are ineffective against human Babesia microti and six Candida sp
CN111514157A (zh) 组合物在制备兽用抗寄生虫病药物中的应用、兽用抗寄生虫病的透皮溶液及其制备方法
Khan et al. Assessment of bioequivalence of ciprofloxacin in healthy male subjects using HPLC.
US20220378758A1 (en) Rifaximin liquid formulations
Pahwa et al. Diversified beauty of Saccharomyces boulardii
Sumano-López et al. Administration of ciprofloxacin and capsaicin in rats to achieve higher maximal serum concentrations
Trinh et al. Anti-malarial activity of HCl salt of SKM13 (SKM13-2HCl)
CN109481692A (zh) 一种青蒿琥酯肝素衍生物及其药物组合物和应用
CN105982886A (zh) 青蒿素衍生物在制备酒渣鼻治疗药物上的应用
CN110946862A (zh) 血根碱在抑制多重耐药霍氏肠杆菌生长中的应用
US20250295615A1 (en) Combinations of curcumin and ursolic acid and uses thereof
CN1290495C (zh) 一种细辛脑脂微球制剂及其制备方法
Ewuziea et al. A Review of gentamicin sulphate oral preparation containing natural oil (pumpkin seed oil) for systemic indication

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20111228

Termination date: 20210515

CF01 Termination of patent right due to non-payment of annual fee